Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.40 |
| ▸ | CCNH | P51946 | 1/20 | 0.40 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.40 |
| ▸ | BPTF | Q12830 | 2/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | IDH2 | P48735 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28729081 | 1.00 | SYK (0.41) | SYKKCNH2MAPK3MAPK1AURKB | |
| SCHEMBL31736623 | 0.89 | IGF1R (0.46) | MAPK1 | |
| Trifluoroacetic Acid SCHEMBL28549612 | 0.86 | HRH4 (0.51) | SYKKCNH2MAPK3MAPK1AURKB | |
| Trifluoroacetic Acid SCHEMBL28549613 | 0.86 | HRH4 (0.51) | SYKKCNH2MAPK3MAPK1AURKB | |
| SCHEMBL3631883 | 0.86 | SYK (0.44) | SYKKCNH2MAPK3MAPK1AURKB | |
| SCHEMBL20577264 | 0.86 | SYK (0.44) | SYKKCNH2MAPK3MAPK1AURKB | |
| SCHEMBL20577266 | 0.86 | SYK (0.44) | SYKKCNH2MAPK3MAPK1AURKB | |
| SCHEMBL20576709 | 0.83 | CCNK (0.46) | SYKKCNH2MAPK3MAPK1AURKB | |
| SCHEMBL17961848 | 0.83 | CCNT1 (0.41) | SYKKCNH2MAPK3MAPK1AURKB | |
| SCHEMBL22895339 | 0.83 | MAPK1 (0.56) | MAPK1CDK7CCNHMNAT1BPTF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388990-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | KINNATE BIOPHARMA INC. | 2022-12-08 | — | — | US | disclosed |
| US-11358958-B2 | — | — | 2022-06-14 | — | — | US | disclosed |
| EP-3999498-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | Kinnate Biopharma Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| CN-114401955-A | Inhibitors of cyclin dependent kinases | 金耐特生物制药公司 | 2022-04-26 | — | — | CN | disclosed |
| US-20210130340-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | KINNATE BIOPHARMA INC. | 2021-05-06 | — | — | US | disclosed |
| WO-2021011796-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | KINNATE BIOPHARMA INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| US-10894788-B2 | Inhibitors of cyclin-dependent kinases | KINNATE BIOPHARMA INC. (US) | 2021-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358958-B2 | — | CDK2, CDK1, CDK6 | SYK 3504/4885KCNH2 4582/4885MAPK3 527/4885 |
| US-20210130340-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK2, CCNK, CDK1 | SYK 2845/4885KCNH2 4484/4885MAPK3 379/4885 |
| US-10894788-B2 | Inhibitors of cyclin-dependent kinases | CDK2, CCNK, CDK1 | SYK 2845/4885KCNH2 4484/4885MAPK3 379/4885 |
| US-20220388990-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK2, CCNK, CDK1 | SYK 2654/4885KCNH2 4416/4885MAPK3 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.